The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MTSR | N/A | N/A | N/A | +166% |
| S&P | +13.19% | +87.83% | +13.42% | +11% |
Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.02M | 0.0% |
| Market Cap | $5.50B | 0.0% |
| Market Cap / Employee | $41.65M | 0.0% |
| Employees | 132 | 0.0% |
| Net Income | -$116.23M | 0.0% |
| EBITDA | -$78.70M | 0.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $448.46M | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.06M | 0.0% |
| Short Term Debt | $2.99M | 0.0% |
| Current | YOY Change | |
|---|---|---|
| Return On Invested Capital | -42.06% | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$81.72M | 0.0% |
| Operating Free Cash Flow | -$81.72M | 0.0% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change | |
|---|---|---|---|---|---|
| Price to Book | -11.28 | 5.90 | 12.22 | - | |
| Price to Tangible Book Value | -8.31 | 7.24 | 15.66 | - | |
| Enterprise Value to EBITDA | -34.60 | -34.10 | -64.26 | - | |
| Total Debt | $10.19M | $10.05M | $1.36M | $3.05M | 222.41% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
